

### C3

## Health-Related Quality of Life (HRQL) in Patients With Uncontrolled Neuroendocrine Tumor (NET) Symptoms

Jennifer L Beaumont, MS<sup>1</sup>, Maureen Neary, PhD<sup>2</sup>, Zhimei Liu, PhD<sup>2</sup>, James C. Yao, MD<sup>3</sup>, David Cella, PhD<sup>1</sup>

<sup>1</sup>Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago IL

<sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover NJ

<sup>3</sup>Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston TX

**Background:** The HRQL of patients with NET may be impacted by treatment and severity of symptoms. The objective of this project was to explore the HRQL impact of uncontrolled symptoms, namely diarrhea, in a cross-sectional survey.

**Methods:** Patients with NET were invited via email to participate in an online anonymous survey consisting of demographics, disease-related questions and standardized measures of HRQL (SF-36 and PROMIS-29). We compared HRQL scores between groups of patients defined by whether or not they were currently receiving any treatment (yes vs no) and stratified by symptom severity (0-3 vs 4 or more bowel movements per day).

**Results:** Of the 663 patients who participated in the survey, 637 provided complete responses to questions about treatment and symptoms and 149 (23%) had not received treatment of any kind in the past month. Patients with 0-3 bowel movements per day reported HRQL scores similar to the general population mean of 50, regardless of whether or not they were receiving treatment. Patients with 4 or more bowel movements per day reported HRQL scores worse than the general population, although those who were not treated reported better physical functioning scores than treated patients (see Table).

**Conclusions:** In this cross-sectional study, HRQL was negatively impacted by diarrhea, although physical functioning was somewhat better in treated patients. Longitudinal reports of HRQL are needed to evaluate the HRQL impact of symptom improvement.

**Table.** Mean PROMIS-29 and SF-36 Scores in patients with 4 or more bowel movements per day

	Treatment	No Treatment	p-value
n	179	35	
PROMIS			
Physical Function (+)	41	44	0.062
Social Role (+)	42	45	0.217
Anxiety (-)	56	56	0.881
Depression (-)	54	53	0.624
Fatigue (-)	59	59	0.983
Pain Interference (-)	56	55	0.499
Sleep Disturbance (-)	55	55	0.792
SF-36			
Physical Functioning (+)	36	41	0.020
Role Limitation – Physical (+)	34	38	0.066
Pain (+)	41	43	0.462
General Health (+)	34	35	0.431
Mental Health (+)	46	47	0.588
Role Limitation – Emotional (+)	41	41	0.886
Social Functioning (+)	41	42	0.599
Vitality (+)	37	38	0.855

Higher scores indicate better functioning (+) or greater levels of symptoms (-)